Diphenoxylate
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Diphenoxylate: From Diarrheal Disease to Gastroduodenitis
One-Sentence Summary
Diphenoxylate is an opioid-type antidiarrheal agent, originally used to treat diarrheal disease. The TxGNN model predicts it may be effective for gastroduodenitis, but this prediction is supported by 0 clinical trials and 0 publications, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Diarrheal disease (the Singapore licence records contain no approved indication text) |
| Predicted New Indication | Gastroduodenitis |
| TxGNN Prediction Score | 90.83% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology, diphenoxylate is a peripheral mu-opioid receptor agonist that reduces gastrointestinal motility and secretion. This explains its efficacy in diarrheal disease.
That mechanism does not clearly extend to gastroduodenitis. Gastroduodenitis is inflammation of the upper GI mucosa, and slowing motility offers no obvious benefit. It could even be unhelpful. The TxGNN score is high (90.83%), but no trials or literature were found to back it. The prediction should be treated as a hypothesis only.
Other predicted indications were also reviewed. Most have no supporting evidence and no plausible mechanism, such as peptic ulcer disease, common cold, pharyngitis, parkinsonian disorder and exercise-induced malignant hyperthermia. Two are worth noting:
- Gastroenteritis (score 87.33%) has the most literature, but it largely duplicates the existing diarrhea use. It is symptomatic relief, not a new disease target.
- Irritable bowel syndrome (score 78.96%) has only class-level evidence, mostly on loperamide and opioid ligands. None of it tests diphenoxylate directly.
Clinical Trial Evidence
Currently no related clinical trials registered for gastroduodenitis.
Literature Evidence
Currently no related literature available for gastroduodenitis.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN05379P | DHAMOTIL TABLET | Film-coated tablet | Not stated |
| SIN09095P | SUN-DIANOX TABLET | Tablet | Not stated |
Safety Considerations
- Contraindications (from the knowledge graph, not label text): kidney disease, liver disease, gallbladder disease, biliary tract disease, obstructive jaundice, hepatorenal syndrome, substance abuse/dependence, Clostridium difficile colitis, perinatal necrotizing enterocolitis, angle-closure glaucoma, dysentery, shigellosis, and infectious diarrheal or intestinal infectious disease.
- Drug Interactions: 61 interactions were recorded, and the 20 listed in the data are all of moderate severity. Examples include baclofen, carbamazepine, carisoprodol, cetirizine, citalopram, clobazam, chloral hydrate, cannabidiol and desvenlafaxine. Many are CNS depressants or sedating agents, so additive sedation is the main concern.
- Other signals from the literature: a 2024 case report describes diphenoxylate toxicity in a young child with acute gastroenteritis, with respiratory and central nervous system depression. The combination product also contains atropine, which impairs sweating and has anticholinergic effects.
Please refer to the package insert for the official warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for gastroduodenitis has no clinical trials or literature (evidence level L5), and the drug's antimotility mechanism offers no clear benefit for upper GI mucosal inflammation. The knowledge-graph contraindications and the pediatric toxicity report add further caution.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA, to complete the safety screen
- Detailed mechanism of action data (MOA)
- Mechanistic or preclinical evidence supporting a benefit in gastroduodenitis
- Any direct clinical studies of diphenoxylate in upper GI inflammatory conditions
- If a repurposing direction is pursued, gastroenteritis symptom control or diarrhea-predominant IBS has more indirect support, but both largely overlap with the existing use and would need a clearly differentiated research question
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.